Country
Clinical Trials in Burkina Faso
Studies with at least one site in Burkina Faso. Open a trial for its sites in Burkina Faso, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 24Acute Malnutrition With no Complications
Effectiveness of an Alternative Protocol in the Management of Acute Malnutrition
This experimental study aims to test an alternative protocol for managing acute malnutrition in children aged 6-59 months in Burkina Faso.
- Trial name
- Alternat-MAL (NCT06792370)
- Testing
- ready-to-use therapeutic food (for children with MAM), Ready-to-use supplementary food, Ready to Use Therapeutic Food - Reduced dose 1
- Where
- Burkina Faso
- Volunteers
- 3,521 people
- Sponsor
- Institut de Recherche en Sciences de la Sante, Burkina Faso
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Older Adults
Frailty, Geriatric Syndromes and Care Pathways of Older Adults Living With HIV in West Africa
With currently available antiretroviral therapy, people living with HIV (PLWHIV) are living longer. This exposure to HIV and combination antiretroviral therapy may accelerate the aging of this population, thus increasing the…
- Trial name
- NCT07355413
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Anemia, Iron Deficiency
Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal and Newborn Hemoglobin and Iron Status
The World Health Organization (WHO) currently recommends the pregnant women receive iron-containing supplements and, in settings where calcium intake is low, calcium supplements.
- Trial name
- CaMMS (NCT06568315)
- Testing
- Concurrent multiple micronutrient and calcium supplementation, Separate multiple micronutrient and calcium supplementation
- Where
- 2 sites in Burkina Faso, Pakistan
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Malaria, PLASMODIUM FALCIPARUM MALARIA
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda.
- Trial name
- AVERT (NCT07749911)
- Testing
- R21/Matris-M Malaria vaccine
- Where
- 21 sites in Burkina Faso, Uganda
- Volunteers
- 20,000 people
- Sponsor
- Clinton Health Access Initiative Inc.
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Retinoblastoma
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and…
- Trial name
- GFARB12019 (NCT04425434)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 3,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Burkitt Lymphoma
Recommendations for the Treatment of Children With Burkitt's Lymphoma
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units…
- Trial name
- GFALMB2019 (NCT04425421)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Nephroblastoma
Therapeutic Recommendations for Nephroblastoma
The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
- Trial name
- GFANEPHRO20 (NCT04423484)
- Testing
- Data collection
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Completed, with results posted
All 40Severe Acute Malnutrition
Mother Screening for Relapse Using Mid-upper Arm Circumference Among Children Recovered From Severe Acute Malnutrition
The investigators propose a pilot randomized controlled trial to train mothers to screen their children post-discharge for relapse based on MUAC criteria to facilitate timely identification and referral to care for children who…
- Trial name
- NCT05932992
- Testing
- Mother education on how to perform MUAC assessment
- Where
- Burkina Faso
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Schistosomiasis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
The goal of this phase 1b, multicenter, randomized, placebo-controlled, observer-blinded, dose-escalation study is to assess the safety, tolerability, and immunogenicity of a three-dose regimen, spaced four weeks apart, given…
- Trial name
- NCT05762393
- Testing
- rSm-p80 + GLA-SE
- Where
- 2 sites in Burkina Faso, Madagascar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Severe Malaria
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.
- Trial name
- NCT04675931
- Testing
- Cipargamin, IV Artesunate, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Malaria Infection
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and…
- Trial name
- NCT05974267
- Testing
- M5717 60 mg, Pyronaridine, Atovaquone-Proguanil
- Where
- 4 sites in Burkina Faso, Kenya and 2 more
- Volunteers
- 192 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany